Valeant Pharmaceuticals International beat Q1 estimates and raised its guidance, but it also announced the departure of the CFO who’s overseen finances during its period of greatest growth. Valeant (VRX) early Wednesday posted revenue of $2.19 billion, up 16% from the year-earlier quarter and $40 million above analysts’ consensus, according to Thomson Reuters. Cash earnings per share rose 10% to $2.36, 2 cents above views. The company added more
Canadian specialty-drug giant Valeant Pharmaceuticals International (VRX) beat Q1 estimates and raised its guidance, but it also announced the departure of the CFO who’s overseen finances during its period of greatest growth. Valeant early Wednesday posted revenue of $2.19 billion, up 16% from the year-earlier quarter and about $40 million above analysts’ consensus, according to Thomson Reuters. Cash earnings per share rose 10% to $2.36, beating
Specialty drugmaker Endo International withdrew its offer for Salix Pharmaceuticals Monday after Valeant Pharmaceuticals International enlarged its buyout deal. Investors seemed happy, as all three stocks went up. Valeant (VRX) raised its offer to $173 a share cash, or $11.1 billion, up from the $158 a share the two companies agreed to last month. The new terms also added $100 million to the breakup fee, which now amounts to $7 a